Abrocitinib
Abrocitinib is an oral, small molecule, Janus kinase (JAK) 1 inhibitor mukugadzirwa kwekurapa kwevakuru nevechiri kuyaruka vane pakati kusvika kune yakanyanya atopic dermatitis.
Abrocitinib iri kuferefetwa mukuedzwa kwekiriniki NCT03796676 (JAK1 Inhibitor Ine Medicated Topical Therapy in Adolescents With Atopic Dermatitis).
Abrocitinib parizvino iri kugadzirwa nePfizer yekurapa atopic dermatitis (eczema). Iyo yekuferefeta yemuromo kamwe-zuva nezuva Janus kinase 1 (JAK1) inhibitor.
Atopic dermatitis (AD) chirwere cheganda chakaoma, chisingaperi, chinoratidzwa ne pruritic, kukwenya kwakanyanya, uye maronda eeczematous anobata chikamu che25% chevana uye 2% kusvika 3% yevakuru pasi rose. Abrocitinib is selective inhibitor yeJanus kinase-1 (JAK1) enzyme inhibiting the inflammatory process. Naizvozvo, isu takavavarira kuongorora kushanda uye kuchengetedzwa kweabrocitinib yepakati-kusvika-yakanyanya AD.
Abrocitinib in dose 100 mg kana 200 mg mushonga unoshanda, unobvumirwa zvakanaka, uye unovimbisa mukurapa varwere vane pakati-kusvika-yakanyanya atopic dermatitis. Zvisinei, kuongorora kwaifarira kushanda kweabrocitinib 200 mg pamusoro pe100 mg, asi migumisiro yakadai sekusvotwa uye musoro zvinogona kuitika zvakanyanya ne200 mg.
Proposal18Quality Consistency Evaluation mapurojekiti akatenderwa4,uye6mapurojekiti ari pasi pekubvumidzwa.
Yepamberi yepasirese yemhando manejimendi system yakaisa hwaro hwakasimba hwekutengesa.
Kutariswa kwemhando yepamusoro kunomhanya kuburikidza nehupenyu hwese kutenderera kwechigadzirwa kuti ive nechokwadi chemhando uye yekurapa maitiro.
Professional Regulatory Affairs timu inotsigira zvinodiwa zvemhando panguva yekushandisa uye kunyoreswa.
Korea Countec Bottled Packaging Line
Taiwan CVC Bottled Packaging Line
Italy CAM Board Packaging Line
German Fette Compacting Machine
Japan Viswill Tablet Detector
DCS Control Room
